Tesamorelin is a synthetic analogue of GHRH stabilised with a trans-3-hexenoic acid N-terminal modification to resist DPP-IV degradation. The only GHRH-based peptide with FDA approval (as Egrifta® for HIV-associated lipodystrophy), providing a uniquely strong clinical evidence foundation.
- FDA-approved pharmacological profile — the only research GHRH analogue with an approved clinical indication.
- Selective pituitary GH stimulation — activates GHRH receptors without direct glucocorticoid or prolactin crosstalk.
- Visceral adipose tissue research — clinical trials documented −15% to −18% trunk/visceral fat reduction in 26-week studies.
- Cognitive and neurological research — emerging data suggests GH/IGF-1 axis stimulation improves cognitive function.
⚠️ For research use only. Not for human or animal consumption. Store at −20°C. Reconstitute with Bacteriostatic Water.
Reviews
There are no reviews yet.